Learn more about the LINC-4 trial: a clinical study for people confirmed with persistent or recurrent Cushing’s disease
Novartis is now recruiting participants who have Cushing’s disease. By participating in this study, you may receive an investigational drug called osilodrostat (LCI699).
All patients will receive study-related care from a research team of health care professionals at a clinical trial site while participating.
Osilodrostat is an investigational drug. Efficacy and safety have not been established. There is no guarantee that osilodrostat will become commercially available.
As with all clinical trials, you have the right to leave the study at any time, for any reason.